CO6660443A2 - Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg) - Google Patents
Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg)Info
- Publication number
- CO6660443A2 CO6660443A2 CO12216949A CO12216949A CO6660443A2 CO 6660443 A2 CO6660443 A2 CO 6660443A2 CO 12216949 A CO12216949 A CO 12216949A CO 12216949 A CO12216949 A CO 12216949A CO 6660443 A2 CO6660443 A2 CO 6660443A2
- Authority
- CO
- Colombia
- Prior art keywords
- peg
- polyethylene glycol
- factor viii
- blood coagulation
- conjugated factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1007357.5A GB201007357D0 (en) | 2010-04-30 | 2010-04-30 | Conjugated factor VIII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6660443A2 true CO6660443A2 (es) | 2013-04-30 |
Family
ID=42289987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12216949A CO6660443A2 (es) | 2010-04-30 | 2012-11-29 | Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg) |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20130150302A1 (enExample) |
| EP (1) | EP2563402A1 (enExample) |
| JP (1) | JP5870088B2 (enExample) |
| KR (1) | KR20130055619A (enExample) |
| CN (1) | CN102939108A (enExample) |
| AP (1) | AP2012006575A0 (enExample) |
| AU (1) | AU2011247147B2 (enExample) |
| BR (1) | BR112012027590A2 (enExample) |
| CA (1) | CA2797058A1 (enExample) |
| CL (1) | CL2012003039A1 (enExample) |
| CO (1) | CO6660443A2 (enExample) |
| CR (1) | CR20120579A (enExample) |
| EA (1) | EA201290938A1 (enExample) |
| EC (1) | ECSP12012314A (enExample) |
| GB (2) | GB201007357D0 (enExample) |
| IL (1) | IL222566A (enExample) |
| MX (1) | MX2012012683A (enExample) |
| MY (1) | MY160922A (enExample) |
| NI (1) | NI201200160A (enExample) |
| NZ (1) | NZ603939A (enExample) |
| PE (1) | PE20130254A1 (enExample) |
| PH (1) | PH12012502150A1 (enExample) |
| RU (1) | RU2012144555A (enExample) |
| SG (1) | SG184906A1 (enExample) |
| WO (1) | WO2011135307A1 (enExample) |
| ZA (1) | ZA201208989B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2101821T3 (da) | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| BR112012001814A8 (pt) | 2009-07-27 | 2018-02-06 | Baxalta GmbH | Conjugados de proteína de coagulação sanguínea |
| ES2800983T3 (es) | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
| HK1200695A1 (en) * | 2012-04-16 | 2015-08-14 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
| CN117467019A (zh) | 2018-05-18 | 2024-01-30 | 郑州晟斯生物科技有限公司 | 改进的fviii融合蛋白及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1596887B1 (en) * | 2003-02-26 | 2022-03-23 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| DK2371856T3 (en) * | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| AU2005322067B8 (en) * | 2004-12-27 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Polymer-von Willebrand factor-conjugates |
| WO2007126808A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
| US20100239517A1 (en) | 2007-10-09 | 2010-09-23 | Stephen Brocchini | Novel conjugated proteins and peptides |
| KR20110016440A (ko) * | 2008-04-24 | 2011-02-17 | 셀틱 파르마 피이지 엘티디. | 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체 |
| ES2560807T3 (es) | 2008-07-21 | 2016-02-22 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
| GB0912485D0 (en) * | 2009-07-17 | 2009-08-26 | Polytherics Ltd | Improved conjugation method |
-
2010
- 2010-04-30 GB GBGB1007357.5A patent/GB201007357D0/en not_active Ceased
-
2011
- 2011-04-28 SG SG2012077087A patent/SG184906A1/en unknown
- 2011-04-28 CN CN2011800218881A patent/CN102939108A/zh active Pending
- 2011-04-28 PE PE2012002104A patent/PE20130254A1/es not_active Application Discontinuation
- 2011-04-28 WO PCT/GB2011/000662 patent/WO2011135307A1/en not_active Ceased
- 2011-04-28 NZ NZ603939A patent/NZ603939A/xx not_active IP Right Cessation
- 2011-04-28 MX MX2012012683A patent/MX2012012683A/es not_active Application Discontinuation
- 2011-04-28 BR BR112012027590A patent/BR112012027590A2/pt not_active IP Right Cessation
- 2011-04-28 CA CA2797058A patent/CA2797058A1/en active Pending
- 2011-04-28 MY MYPI2012004710A patent/MY160922A/en unknown
- 2011-04-28 AU AU2011247147A patent/AU2011247147B2/en not_active Ceased
- 2011-04-28 US US13/643,287 patent/US20130150302A1/en not_active Abandoned
- 2011-04-28 EA EA201290938A patent/EA201290938A1/ru unknown
- 2011-04-28 PH PH1/2012/502150A patent/PH12012502150A1/en unknown
- 2011-04-28 AP AP2012006575A patent/AP2012006575A0/xx unknown
- 2011-04-28 KR KR1020127031386A patent/KR20130055619A/ko not_active Ceased
- 2011-04-28 JP JP2013506735A patent/JP5870088B2/ja not_active Expired - Fee Related
- 2011-04-28 EP EP11719040A patent/EP2563402A1/en not_active Withdrawn
- 2011-04-28 RU RU2012144555/15A patent/RU2012144555A/ru not_active Application Discontinuation
- 2011-04-28 GB GB201220667A patent/GB2492935B8/en not_active Expired - Fee Related
-
2012
- 2012-10-21 IL IL222566A patent/IL222566A/en not_active IP Right Cessation
- 2012-10-29 NI NI201200160A patent/NI201200160A/es unknown
- 2012-10-29 CL CL2012003039A patent/CL2012003039A1/es unknown
- 2012-11-14 CR CR20120579A patent/CR20120579A/es unknown
- 2012-11-28 ZA ZA2012/08989A patent/ZA201208989B/en unknown
- 2012-11-28 EC ECSP12012314 patent/ECSP12012314A/es unknown
- 2012-11-29 CO CO12216949A patent/CO6660443A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012314A (es) | Factor viii conjugado para coagulación de la sangre | |
| ECSP12012315A (es) | FACTOR VIIa CONJUGADO PARA COAGULACIÓN DE LA SANGRE | |
| MX362432B (es) | Variantes de oxm pegilada. | |
| CY1121419T1 (el) | Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης | |
| CY1121560T1 (el) | Ανοσογονικη συνθεση | |
| BR112012017488A2 (pt) | "dispositivo" | |
| UY37922A (es) | Composiciones farmacéuticas que comprenden un profármaco deadrenomedulina basado en polietilenglicol | |
| BR112015015319A2 (pt) | composições de nanopartícula de albumina e paclitaxel | |
| CL2021001142A1 (es) | Nuevos conjugados citostáticos con ligandos de integrina | |
| GT201200339A (es) | Compuestos, composiciones de tioacetato y mètodos de uso | |
| BRPI0917920B8 (pt) | expansão direcional de dispositivos intraluminais | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| BR112012010037A2 (pt) | artigo de tubo médico | |
| MX2011009808A (es) | Agentes de elaboracion de imagen optica. | |
| BRPI0920108A2 (pt) | peptídomimético cíclico contendo argina, glicina, ácido aspártico (rgd), conjugado de peptidomimético cíclico contendo rgd, composição farmacêutica, conjugado e uso do mesmo. | |
| CU20130128A7 (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| BR112012003800A2 (pt) | composição, peptídeo, e formulação farmacêutica. | |
| CY1117854T1 (el) | Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση | |
| AR081928A1 (es) | Composicion de inmunoglobulinas humanas estabilizada | |
| CY1115734T1 (el) | Συνθεσεις benzenesulfonamide, μεθοδος συνθεσης τους, και χρηση αυτων στην ιατρικη | |
| CY1118967T1 (el) | Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης | |
| BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
| CL2011002893A1 (es) | Peptido derivado del factor viii; composicion que lo comprende; uso para aumentar la tolerancia a factor viii en individuos que padecen o estan en riesgo de padecer hemofilia a o hemofilia adquirida. | |
| CL2009001083A1 (es) | Variantes de receptores de la proteina c3 de complemento (crig), molecula quimerica y composicion farmaceutica que las comprende; uso de las variantes para preparar un medicamento para prevenir o tratar una enfermedad asociada al complemento, tal como una enfermedad inflamatoria o autoinmune. | |
| ATE529096T1 (de) | Pharmazeutische zusammensetzungen mit bradykinin- antagonisten und hyaluronsäure sowie anwendungen davon |